Candidozyma auris (Candida auris) as a harbinger of novel fungal pathogens
- 1Chair for Computational and Theoretical Biology, University of Würzburg, Würzburg, Germany
- 2Joint Institute for Individualisation in a Changing Environment (JICE), University of Würzburg, Würzburg, Germany
Abstract
Mammals are protected from fungal pathogens by two evolutionary pillars: adaptive immunity and elevated body temperature. Anthropogenic climate change is eroding this thermal barrier, while a concurrent decline in human basal body temperature accelerates convergence from both directions. Candida auris, a thermotolerant, multidrug-resistant pathogen, arose independently as genetically distinct clades on multiple continents, a pattern implicating shared selective pressures rather than clonal spread. Unlike its closest relatives, which grow poorly at mammalian temperatures, it thrives at 37°C, tolerates up to 47°C, persists on hospital surfaces, resists all three major antifungal classes, and causes invasive infections with 30–60% mortality. We review its evolutionary biology, ecology, and clinical significance, evaluating hypotheses for its origin, and the mechanisms underlying its thermotolerance and virulence. C. auris may be the first of many fungi adapting to breach mammalian thermal defenses, making predictive frameworks for fungal disease emergence an urgent priority.
Related
- Candidozyma auris (formerly Candida auris): A P6 medicine framework integrating genomics, surveillance and the prevention of multidrug-resistant fungal threats.
- Repurposing the phospholipase A2 inhibitor, darapladib, to combat multidrug-resistant fungal pathogens, including Candida auris
- Fungicidal effects of eight disinfectants against resistant Candidozyma auris (formerly Candida auris), Aspergillus fumigatus, and Trichophyton indotineae
- Antifungal activity of the nucleoside mimetic 5-fluorouridine against Candidozyma auris and Candida species
- Antimicrobial Peptoids Show Potent Antifungal Activity against Candidozyma (Candida) auris In Vivo and Broad-Spectrum Activity In Vitro against Other Candida Species.
BibTeX
@article{schuh2026candidozyma,
title = {{Candidozyma auris (Candida auris) as a harbinger of novel fungal pathogens}},
author = {Carla E. Schuh and Chaitanya S. Gokhale},
journal = {mSphere},
year = {2026},
month = oct,
doi = {10.1128/msphere.00109-26},
url = {https://doi.org/10.1128/msphere.00109-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Candidozyma auris (Candida auris) as a harbinger of novel fungal pathogens
AU - Carla E. Schuh
AU - Chaitanya S. Gokhale
PY - 2026
DA - 2026/10/02
JO - mSphere
DO - 10.1128/msphere.00109-26
UR - https://doi.org/10.1128/msphere.00109-26
AB - Mammals are protected from fungal pathogens by two evolutionary pillars: adaptive immunity and elevated body temperature. Anthropogenic climate change is eroding this thermal barrier, while a concurrent decline in human basal body temperature accelerates convergence from both directions. Candida auris, a thermotolerant, multidrug-resistant pathogen, arose independently as genetically distinct clades on multiple continents, a pattern implicating shared selective pressures rather than clonal spread. Unlike its closest relatives, which grow poorly at mammalian temperatures, it thrives at 37°C, tolerates up to 47°C, persists on hospital surfaces, resists all three major antifungal classes, and causes invasive infections with 30–60% mortality. We review its evolutionary biology, ecology, and clinical significance, evaluating hypotheses for its origin, and the mechanisms underlying its thermotolerance and virulence. C. auris may be the first of many fungi adapting to breach mammalian thermal defenses, making predictive frameworks for fungal disease emergence an urgent priority.
SN - 2379-5042
ER -